Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani

Translated title of the contribution: Direct costs of schizophrenia in Italian community psychiatric services

L. Garattini, C. Rossi, F. Tediosi, C. Cornaggia, G. Covelli, C. Barbui, F. Parazzini

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: To estimate resource utilisation and direct costs of treatment for patients with schizophrenia in Italian Community Mental Health Centers (CMHCs). Design: Multicentre, retrospective observational study. CMHCs recruited all patients who attended a follow-up consultation during the period September to December 1998. At enrolment, psychiatrists completed a questionnaire on consumption of resources in the 2 months before recruitment. Setting. 14 CMHCs. Perspective: Italian National Health Service (INHS). Patients: 702 patients with a diagnosis of schizophrenia or other psychotic disorders, defined according to the Diagnostic and Statistical Manual of Mental Disorders-fourth edition. These patients had been followed by the CMHCs for at least 2 years and attended a follow-up consultation either during the period September to December 1998 or on randomly selected days during this period. Patients were classified into seven groups according to their diagnosis. Results: The mean direct cost of patients with schizophrenia in the 2-month observation period was 2 234 475 Italian lire [L.](1 154.01 Euro; EUR); direct costs ranged from L. 1 545 818 to L. 2 775 658 (EUR798.35 to EUR1 433.51) by prognostic group. There was wide variability for prognostic groups in the impact of most cost components on total cost. Admissions accounted for between 11.4 and 56.3% of the total cost, daycare centre days for between 11.3 and 35.5%, home visits for 7.8 to 16.4%, and day-hospital days for 5.4 to 32.8%. Antipsychotics and anxiolytics were the most prescribed drugs and also the most costly. Conclusions: Despite the limitations of the study related to the short period considered, we believe this study offers some interesting information on the burden of schizophrenia, a disease for which its cost has received limited attention so far in Italy.

Original languageItalian
Pages (from-to)81-89
Number of pages9
JournalPharmacoEconomics - Italian Research Articles
Volume4
Issue number2
Publication statusPublished - 2002

Fingerprint

Community Psychiatry
Social Welfare
Schizophrenia
Community Mental Health Centers
Costs and Cost Analysis
Referral and Consultation
House Calls
Anti-Anxiety Agents
National Health Programs
Diagnostic and Statistical Manual of Mental Disorders
Health Care Costs
Psychotic Disorders
Italy
Antipsychotic Agents
Observational Studies
Psychiatry
Retrospective Studies
Observation

ASJC Scopus subject areas

  • Health Policy
  • Pharmacology

Cite this

Garattini, L., Rossi, C., Tediosi, F., Cornaggia, C., Covelli, G., Barbui, C., & Parazzini, F. (2002). Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani. PharmacoEconomics - Italian Research Articles, 4(2), 81-89.

Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani. / Garattini, L.; Rossi, C.; Tediosi, F.; Cornaggia, C.; Covelli, G.; Barbui, C.; Parazzini, F.

In: PharmacoEconomics - Italian Research Articles, Vol. 4, No. 2, 2002, p. 81-89.

Research output: Contribution to journalArticle

Garattini, L, Rossi, C, Tediosi, F, Cornaggia, C, Covelli, G, Barbui, C & Parazzini, F 2002, 'Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani', PharmacoEconomics - Italian Research Articles, vol. 4, no. 2, pp. 81-89.
Garattini L, Rossi C, Tediosi F, Cornaggia C, Covelli G, Barbui C et al. Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani. PharmacoEconomics - Italian Research Articles. 2002;4(2):81-89.
Garattini, L. ; Rossi, C. ; Tediosi, F. ; Cornaggia, C. ; Covelli, G. ; Barbui, C. ; Parazzini, F. / Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani. In: PharmacoEconomics - Italian Research Articles. 2002 ; Vol. 4, No. 2. pp. 81-89.
@article{51d771e3632f42589fb02eebe6f6d3ac,
title = "Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani",
abstract = "Objective: To estimate resource utilisation and direct costs of treatment for patients with schizophrenia in Italian Community Mental Health Centers (CMHCs). Design: Multicentre, retrospective observational study. CMHCs recruited all patients who attended a follow-up consultation during the period September to December 1998. At enrolment, psychiatrists completed a questionnaire on consumption of resources in the 2 months before recruitment. Setting. 14 CMHCs. Perspective: Italian National Health Service (INHS). Patients: 702 patients with a diagnosis of schizophrenia or other psychotic disorders, defined according to the Diagnostic and Statistical Manual of Mental Disorders-fourth edition. These patients had been followed by the CMHCs for at least 2 years and attended a follow-up consultation either during the period September to December 1998 or on randomly selected days during this period. Patients were classified into seven groups according to their diagnosis. Results: The mean direct cost of patients with schizophrenia in the 2-month observation period was 2 234 475 Italian lire [L.](1 154.01 Euro; EUR); direct costs ranged from L. 1 545 818 to L. 2 775 658 (EUR798.35 to EUR1 433.51) by prognostic group. There was wide variability for prognostic groups in the impact of most cost components on total cost. Admissions accounted for between 11.4 and 56.3{\%} of the total cost, daycare centre days for between 11.3 and 35.5{\%}, home visits for 7.8 to 16.4{\%}, and day-hospital days for 5.4 to 32.8{\%}. Antipsychotics and anxiolytics were the most prescribed drugs and also the most costly. Conclusions: Despite the limitations of the study related to the short period considered, we believe this study offers some interesting information on the burden of schizophrenia, a disease for which its cost has received limited attention so far in Italy.",
author = "L. Garattini and C. Rossi and F. Tediosi and C. Cornaggia and G. Covelli and C. Barbui and F. Parazzini",
year = "2002",
language = "Italian",
volume = "4",
pages = "81--89",
journal = "PharmacoEconomics - Italian Research Articles",
issn = "1590-9158",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Costi diretti della schizofrenia nei dipartimenti di salute mentale italiani

AU - Garattini, L.

AU - Rossi, C.

AU - Tediosi, F.

AU - Cornaggia, C.

AU - Covelli, G.

AU - Barbui, C.

AU - Parazzini, F.

PY - 2002

Y1 - 2002

N2 - Objective: To estimate resource utilisation and direct costs of treatment for patients with schizophrenia in Italian Community Mental Health Centers (CMHCs). Design: Multicentre, retrospective observational study. CMHCs recruited all patients who attended a follow-up consultation during the period September to December 1998. At enrolment, psychiatrists completed a questionnaire on consumption of resources in the 2 months before recruitment. Setting. 14 CMHCs. Perspective: Italian National Health Service (INHS). Patients: 702 patients with a diagnosis of schizophrenia or other psychotic disorders, defined according to the Diagnostic and Statistical Manual of Mental Disorders-fourth edition. These patients had been followed by the CMHCs for at least 2 years and attended a follow-up consultation either during the period September to December 1998 or on randomly selected days during this period. Patients were classified into seven groups according to their diagnosis. Results: The mean direct cost of patients with schizophrenia in the 2-month observation period was 2 234 475 Italian lire [L.](1 154.01 Euro; EUR); direct costs ranged from L. 1 545 818 to L. 2 775 658 (EUR798.35 to EUR1 433.51) by prognostic group. There was wide variability for prognostic groups in the impact of most cost components on total cost. Admissions accounted for between 11.4 and 56.3% of the total cost, daycare centre days for between 11.3 and 35.5%, home visits for 7.8 to 16.4%, and day-hospital days for 5.4 to 32.8%. Antipsychotics and anxiolytics were the most prescribed drugs and also the most costly. Conclusions: Despite the limitations of the study related to the short period considered, we believe this study offers some interesting information on the burden of schizophrenia, a disease for which its cost has received limited attention so far in Italy.

AB - Objective: To estimate resource utilisation and direct costs of treatment for patients with schizophrenia in Italian Community Mental Health Centers (CMHCs). Design: Multicentre, retrospective observational study. CMHCs recruited all patients who attended a follow-up consultation during the period September to December 1998. At enrolment, psychiatrists completed a questionnaire on consumption of resources in the 2 months before recruitment. Setting. 14 CMHCs. Perspective: Italian National Health Service (INHS). Patients: 702 patients with a diagnosis of schizophrenia or other psychotic disorders, defined according to the Diagnostic and Statistical Manual of Mental Disorders-fourth edition. These patients had been followed by the CMHCs for at least 2 years and attended a follow-up consultation either during the period September to December 1998 or on randomly selected days during this period. Patients were classified into seven groups according to their diagnosis. Results: The mean direct cost of patients with schizophrenia in the 2-month observation period was 2 234 475 Italian lire [L.](1 154.01 Euro; EUR); direct costs ranged from L. 1 545 818 to L. 2 775 658 (EUR798.35 to EUR1 433.51) by prognostic group. There was wide variability for prognostic groups in the impact of most cost components on total cost. Admissions accounted for between 11.4 and 56.3% of the total cost, daycare centre days for between 11.3 and 35.5%, home visits for 7.8 to 16.4%, and day-hospital days for 5.4 to 32.8%. Antipsychotics and anxiolytics were the most prescribed drugs and also the most costly. Conclusions: Despite the limitations of the study related to the short period considered, we believe this study offers some interesting information on the burden of schizophrenia, a disease for which its cost has received limited attention so far in Italy.

UR - http://www.scopus.com/inward/record.url?scp=0036402565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036402565&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0036402565

VL - 4

SP - 81

EP - 89

JO - PharmacoEconomics - Italian Research Articles

JF - PharmacoEconomics - Italian Research Articles

SN - 1590-9158

IS - 2

ER -